Singapore markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.3800-0.0100 (-0.42%)
At close: 04:00PM EDT
2.3700 -0.01 (-0.42%)
Pre-market: 08:34AM EDT

Seres Therapeutics, Inc.

200 Sidney Street
4th Floor
Cambridge, MA 02139
United States
617 945 9626

Full-time employees431

Key executives

NameTitlePayExercisedYear born
Mr. Eric D. Shaff M.B.A.Pres, CEO & Director1.07MN/A1976
Mr. David A. Arkowitz M.B.A.Exec. VP, CFO & Head of Bus. Devel.670.02kN/A1961
Dr. Matthew R. Henn Ph.D.Exec. VP & Chief Scientific Officer643.83kN/A1975
Ms. Paula A. Cloghessy SHRM-SCP, SPHRExec. VP & Chief People Officer521.27kN/A1972
Dr. Lisa von Moltke M.D.Exec. VP & Chief Medical Officer706.14kN/A1959
Dr. David S. Ege Ph.D.Exec. VP & Chief Technology OfficerN/AN/A1975
Mr. Carlo Tanzi Ph.D.Investor Relations OfficerN/AN/AN/A
Mr. Thomas J. DesRosier Esq., J.D.Chief Legal Officer, Exec. VP & Sec.N/AN/A1955
Dr. Teresa L. Young Ph.D., R.Ph.Exec. VP and Chief Commercial & Strategy OfficerN/AN/A1967
Ms. Caroline HoldaAssistant Gen. CounselN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Seres Therapeutics, Inc.’s ISS governance QualityScore as of 28 September 2023 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.